Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
$ 0.06
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Very low or no dividends
Data is available to registered users only
Data is available to registered users only
About
NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease; and...
Company Valuation
From both historical and forecast perspectives, the stock is fairly priced compared to similar stocks. Specifically, the stock is neutral on EV/EBITDA.
Data is available to registered users only
Buy
Sell